Photo by Pixabay on Pexels.com
KUALA LUMPUR — MBSB Research has maintained a POSITIVE outlook on the healthcare sector following strong 4QFY25 earnings in the US and Europe, driven largely by pharmaceuticals. Demand for GLP-1 drugs, used in diabetes and obesity treatment, lifted pharmaceutical performance, while US hospitals reported resilient inpatient volumes despite labour shortages.
Medical devices and equipment also saw higher demand for high-margin treatments, with oncology drugs adding further momentum. Malaysian healthcare players are expected to mirror global trends, supported by medical tourism, government initiatives to reduce medical costs, recovery in the glove sector, and growth in the halal pharmaceutical market. These factors provide additional upside, positioning Malaysia’s healthcare industry for sustained expansion in 2026.
Read More News on Latest Malaysia
Read More News on Business News Malaysia
Read More News on SG Business News
Read More News on World Future TV
Malaysia's SMEs must prioritize cybersecurity amidst rising online threats, employing strategies like Multi-Factor Authentication and…
We expect the benchmark to trade within the 1,725–1,740 range today.
The UAE’s departure from OPEC+ effective May 1, 2026, removes a key pillar of market…
Maxim and Zlata launch tailored insurance, offering accident coverage, support services, and flexible payment options…
AmBank upgrades MISC to Buy, raises TP to RM9.40, citing stronger tanker rates, resilient contracts,…
Steel Hawk Bhd's subsidiary has secured a logistics contract with Petronas Gas, effective from April…
This website uses cookies.